Who Paid My Doc
Melvin Oatis
Child & Adolescent Psychiatry New York, NY Medical Doctor
NPI 1700115227 CMS profile 32237
420 Lexington Ave, Suite 2559, New York, NY 10170
General payments
$35,216
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Melvin Oatis of New York, NY is reported in the CMS Open Payments database as having received $35,216 across 87 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $96 | 1 | |
| 2020 | General | $218 | 2 | |
| 2019 | General | $34,902 | 84 |
Beside peers
- Melvin Oatis
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Melvin Oatis were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Melvin Oatis | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $34,902 | $129 | $42–$419 | $163 |
| 2020 | $218 | $81 | $28–$226 | $114 |
| 2021 | $0 | $115 | $31–$326 | $132 |
| 2022 | $0 | $124 | $40–$382 | $149 |
| 2023 | $96 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $0 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
38
Drug cost
$601
Branded share of claims
34.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Duloxetine Hcl | Generic | 14 | $243 | |
| Bupropion Hcl Sr Bupropion Hcl | Brand | 13 | $206 | |
| Clonazepam | Generic | 11 | $152 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
87 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in New York
Matthew Lorber
Child & Adolescent Psychiatry · New York, NY
Mitchell Cabisudo
Child & Adolescent Psychiatry · New Windsor, NY
Parinda Parikh
Child & Adolescent Psychiatry · White Plains, NY
Jeffrey Newcorn
Child & Adolescent Psychiatry · New York, NY
John Marino
Child & Adolescent Psychiatry · Canandaigua, NY
Iliyan Ivanov
Child & Adolescent Psychiatry · New York, NY
Related records
Child & Adolescent Psychiatry in New York
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.